Lucentis (ranibizumab) / Roche, Novartis 
Welcome,         Profile    Billing    Logout  
 172 Diseases   135 Trials   135 Trials   7089 News 


«12...3233343536373839404142...7475»
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] Insights from survival analyses during 12 years of anti-VEGF therapy for neovascular age-related macular degeneration (Abstract Channel) -  Sep 28, 2020 - Abstract #EURETINA2020EURETINA_485;    
    Modelling with multiple covariates reveals important factors that help prognosticate individual visual trajectories.Using these models, we demonstrate that an eye beginning anti-VEGF therapy is most likely to experience a positive visual outcome within the first 2 years of initiating treatment and that this is typically sustained for 1.1 years. Furthermore, we underline the need for early detection of neovascular AMD and initiation of anti-VEGF therapy as key factors in improving patient outcomes.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] Choroidal neovascular membranes: single injection response rate (Abstract Channel) -  Sep 28, 2020 - Abstract #EURETINA2020EURETINA_467;    
    Only 4/61 patients recurred within a 24 month follow up period. These patients responded well to a second injection and only one of these patients required to be switched over to a treat and extend protocol for maintenance of visual gain.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] Adherence to anti-VEGF treatment in patients with neovascular age-related macular degeneration (nAMD) in Switzerland (Abstract Channel) -  Sep 28, 2020 - Abstract #EURETINA2020EURETINA_466;    
    Nonadherence was associated with loss of vision, lower number of injections that led to extended injection intervals beyond 12 weeks. The results emphasize the importance of adherence to treatment, the need of solutions with greater durability in order to improve and maintain vision, and should be part of counseling patients with nAMD.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Review, Journal:  Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion. (Pubmed Central) -  Sep 27, 2020   
    In a value-based care perspective, systematic evaluation of diagnostic accuracy, treatment indication, protocols, and outcomes of new interventions is needed at an early stage to improve outcomes. The available RCT evidence suggests that treatment of MO secondary to BRVO with anti-VEGF improves visual and anatomical outcomes at six and 12 months.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Four-Year Outcome of Aflibercept for Neovascular Age-Related Macular Degeneration and polypoidal choroidal vasculopathy. (Pubmed Central) -  Sep 25, 2020   
    Intravitreal injections of anti-vascular endothelial growth factor agents such as ranibizumab and aflibercept are the first-line treatment for neovascular age-related macular degeneration (AMD)...In the present study, vision was retained at baseline level after the four-year treatment with aflibercept. The status of ELM, vitreoretinal adhesion, and choroidal thickness were predictive factors for final vision.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Oxymetazoline: reduction of subconjunctival hemorrhage incidence after intravitreal injections. (Pubmed Central) -  Sep 25, 2020   
    Administration of topical oxymetazoline 30 minutes before IVI is a single, harmless, cost-effective intervention that decreases the incidence of subconjunctival hemorrhage. This may considerably improve patient treatment satisfaction and promote compliance to IVI therapy.
  • ||||||||||  Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Clinical Trial,Phase III, Journal:  Mapping From Visual Acuity to EQ-5D, EQ-5D With Vision Bolt-On, and VFQ-UI in Patients With Macular Edema in the LEAVO Trial. (Pubmed Central) -  Sep 24, 2020   
    Models with multiple components better predict utility than those with single components. This article provides a valuable addition to the literature, in which previous mappings in visual acuity have been limited to linear regressions, resulting in unfounded assumptions about the distribution of the dependent variable.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Biomarker, Journal:  OCT Angiography Biomarkers for Predicting Visual Outcomes after Ranibizumab Treatment for Diabetic Macular Edema. (Pubmed Central) -  Sep 23, 2020   
    This article provides a valuable addition to the literature, in which previous mappings in visual acuity have been limited to linear regressions, resulting in unfounded assumptions about the distribution of the dependent variable. For eyes with DME, parafoveal VD in the superficial layer at baseline was an independent predictor for visual improvement after the loading ranibizumab treatment.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] Incidence of glaucoma surgeries related to intravitreal Anti-VEGF injections () -  Sep 23, 2020 - Abstract #ESCRS2020ESCRS_1737;    
    To the best of our knowledge, according to the most recent literature review, this inflated number of glaucoma surgeries related to Anti-VEGF treatment has not been reported worldwide. The incidence of surgical glaucoma among this rising population of patients seems to be a local health problem that requires active discussion for further understanding.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] Angioid streaks complicated by choroidal neovascularization () -  Sep 23, 2020 - Abstract #ESCRS2020ESCRS_1015;    
    CNV was treated with 3 monthly intravitreal injections of ranibizumab. Angioid streaks are a rare pathology that requires regular monitoring and ophthalmological control in order to quickly diagnose a neovascular complication requiring targeted and early treatment with intravitreal injection of Anti VEGF.
  • ||||||||||  Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Biotech
    Journal, HEOR:  Cost-effectiveness of intravitreal conbercept versus other treatments for wet age-related macular degeneration. (Pubmed Central) -  Sep 23, 2020   
    The potential benefits of conbercept, aflibercept, and ranibizumab has been reported in patients with wet age-related macular degeneration (wAMD)...Probabilistic sensitivity analysis (PSA) indicated that IVT-CON yielded the greatest probabilities of cost-effectiveness (about 92%) compared with other strategies. Conbercept is a cost-effective option for the treatment of wAMD in a Chinese healthcare setting.
  • ||||||||||  Zaltrap (ziv-aflibercept IV) / Sanofi, Regeneron, Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] Identifying risk factors for silicone oil droplets in anti-VEGF injections: a quantitative in vitro study () -  Sep 15, 2020 - Abstract #RSLONDON2020RS_LONDON_301;    
    Syringes containing anti-VEGF agents release over 100 times more silicone oil droplets compared to syringes with sterile water, suggesting a possible interaction between the anti-VEGF molecules and SiO. The “Heavy force” technique is associated with an increased number of SiO droplets per trial.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] Temporal Trends in the Treatment of Proliferative Diabetic Retinopathy: An AAO IRIS Registry Analysis () -  Sep 15, 2020 - Abstract #RSLONDON2020RS_LONDON_206;    
    The factors were related to retinal degeneration in DME and can help obtain proper informed consent before treatment. In this cohort analysis of the IRIS Registry, IVI surpassed PRP as the more common method of treating PDR from 2013 to 2017 with bevacizumab administered in more than two-thirds of intravitreal injections.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] Pharmacokinetic (PK) Profile of the Port Delivery System With Ranibizumab (PDS) in the Phase 2 Ladder Trial () -  Sep 15, 2020 - Abstract #RSLONDON2020RS_LONDON_189;    
    P2
    The PDS implant continuously releases ranibizumab for extended durations, including through M16 in the PDS 100 mg/mL arm. These findings provide PK data to support median time to first refill of 15.8 months observed in PDS 100 mg/mL patients, which was associated with sustained visual gains comparable with monthly intravitreal ranibizumab.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] Anti-VEGF Optic Neuropathy (AVON) () -  Sep 15, 2020 - Abstract #RSLONDON2020RS_LONDON_170;    
    We present a consecutive series of patients treated with anti-VEGF agents against age matched controls, noting an increased rate of POAG, OHT, and glaucoma suspect in the IVI group. Interestingly, the rates of POAG and OHT were strongly correlated with the number of IVI.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] Has the Time Come to Re-evaluate the Treatment Paradigm for Diabetic Retinopathy? () -  Sep 15, 2020 - Abstract #RSLONDON2020RS_LONDON_135;    
    Meanwhile, landmark trials showed that patients with moderately severe or severe NPDR were vulnerable to DR progression without treatment, and more likely to achieve DR improvement with anti-VEGF therapy. Given the trend towards greater mean vision gains with greater DR improvement in RIDE/RISE, these data collectively suggest that the time has come to consider earlier intervention to delay progression towards PDR.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] Reduced Incidence of Post-Injection Endophthalmitis with Pre-filled Syringes () -  Sep 15, 2020 - Abstract #RSLONDON2020RS_LONDON_68;    
    However, a lower incidence of endophthalmitis was found for prefilled syringes and in offices where physicians, as opposed to nurses or technicians, drew up the medication. The use of prefilled syringes and increased caution while drawing up of drug from vials may lower the incidence of endophthalmitis.